Voronoi Inc. has identified heteroaryl derivative compounds reported to be useful for the treatment of cancer.

Immunocure Inc. has synthesized quinoline piperazine derivatives reported to be useful for the treatment of cancer.

Assembly Biosciences Inc. has disclosed bicyclic heterocycle compounds reported to be useful for the treatment of cytomegalovirus (CMV) and herpes simplex virus (HSV) infections.

Scientists at China Resources Shenzhen Bay Development Co. Ltd., National Institutes of Pharmaceutical Research & Development, and Research Institute of Tsinghua University in Shenzhen have described macrocyclic compounds acting as ALK tyrosine kinase receptor and/or ALK tyrosine kinase receptor (mutant) inhibitors reported to be useful for the treatment of malignant neoplasms.

Pannex Therapeutics Inc. has divulged pannexin-1 (PANX1; MRS1) inhibitors reported to be useful for the treatment of neuropathic pain and opioid dependency.

Brise Pharmaceutical (Shanghai) Co. Ltd. has identified calcitonin gene-related peptide (CGRP) receptor antagonists reported to be useful for treatment of cerebrovascular and vascular disorders.

The US Department of Veterans Affairs has synthesized substituted aminopiperazine compounds reported to be useful for the treatment of bacterial and fungal infections.

Merck Sharp & Dohme LLC has disclosed compounds acting as GTPase KRAS inhibitors reported to be useful for the treatment of cancer.

Scientists at Fujifilm Corp. and Osaka University have described piperazine derivatives acting as drug efflux pump inhibitors reported to be useful for the treatment of bacterial infections.

Sudo Biosciences Ltd. has divulged non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of scleroderma, radiographic ankylosing spondylitis, type 1 diabetes, idiopathic pulmonary fibrosis, multiple sclerosis, psoriasis, rheumatoid arthritis, Sjögren’s syndrome and systemic lupus erythematosus, among others.